Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
New technology can potentially overcome CAR T-cell limitations

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.04.16
Views: 1706
Rating:

Dr Philip Low - Purdue University, West Lafayette, USA

Dr Philip Low speaks with ecancertv at AACR 2016 about a novel technique to selectively identify tumour cells in vivo.

With potentially toxic side effects to uncontrolled tumour lysis and hard-to-target heterogeneity, Dr Low describes a new method of using fluorescein dye to bridge tumours and T Cells.

By controlling administration rate and relying on large tumour-ligand libraries currently available, Dr Low reports significant tumour reduction at a low cost.

In adjacent human clinical trials, fluorescein dye binding to tumours has also improved tumour visibility and specificity in surgery.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation